From: Advances in biological functions and applications of apoptotic vesicles
Published year | Term | Parental cell | Size of vesicles | Induction method | Isolation method | Function | Target cell | Animal | Applied method | Disease model | Ref. |
---|---|---|---|---|---|---|---|---|---|---|---|
2022 | Apoptotic vesicles | RAW264.7 macrophages | 240.6±115nm | STS and serum-free | Sequential centrifugation | Inhibit osteogenesis and promot adipogenesis of MSCs | Human ADSCs | Nude mice | Implant with collagen sponges or β-TCP | N/A | [74] |
2022 | Apoptotic vesicles | Human BMMSCs | 150.1±14.8nm | STS | Sequential centrifugation | Switch neutrophils NETosis to apoptosis, ameliorate multiple organ dysfunction and improve survival in septic mice | Bone marrow neutrophils | Mice | Inject intravenously | Sepsis | [68] |
2022 | Apoptotic vesicles | Murine BMMSCs | Approximately 50-1000nm | Serum-free and STS, or DCPy with ultralow-power light irradiation | Sequential centrifugation followed by sequential filtering analysis | Promote wound healing and hair growth via activation of Wnt/β-catenin pathway | Skin and hair follicle MSCs | Mice | Inject subcutaneously or intravenously | SLE | [69] |
2022 | Apoptotic vesicles | Human DPSCs | Around 100-800nm | STS | Sequential centrifugation | Transport TUFM to activate ECs autophagy and promote ECs angiogenesis via the TFEB-induced autophagy-lysosome pathway | ECs | Nude mice, beagle dogs | Implant tooth scaffolds filled with ApoEVs subcutaneously in the dorsum(mice), inject ApoEVs gel material into the root canal of the anterior tooth after removal of the pulp(dogs) | N/A | [24] |
2022 | Apoptotic vesicles | Human ESCs and iPSCs | Approximately 50-200nm | STS and serum-free | Sequential centrifugation | Promote mouse skin wound healing via transferring SOX2 into skin MSCs to activate Hippo signaling pathway | Skin MSCs | Mice | Inject intravenously | Skin wound | [62] |
2022 | Apoptotic bodies | Mouse ADSCs | 800-1600nm | STS, desacetylcinobufotalin, hydroxyurea, or hypocrellin B | Sequential centrifugation | Induce M2 polarization of macrophages | Macrophages | Mice | Inject subcutaneously | Skin wound | [61] |
2021 | Apoptotic extracellular vesicles | Mouse T cells | 200-2000nm | T cell-depleting nanoparticles with Fas-ligand | Sequential centrifugation | Promote macrophages transformation towards the M2 phenotype | Macrophages, BMMSCs | Mice | Induce ApoEVs production in vivo | Osteoporosis | [73] |
2021 | Apoptotic bodies | Human UCMSCs | 200-3000nm | UVC light | Sequential centrifugation | Induce macrophages immunomodulation, cell proliferation, and angiogenesis | Macrophages, human endometrial stromal cells, ECs | Mice, rats | Load into a hyaluronic acid hydrogel and inject in situ | Acute endometrial damage (mice), intrauterine adhesions (rat) | [67] |
2021 | Apoptotic bodies | Rat bone marrow neutrophils | 800-1200nm (Neu-ABs), 100-400nm (eNABs) | STS | Sequential centrifugation | Inflammation-tropism and immunoregulatory effects | Macrophages | Rats | Inject intravenously | Myocardial infarction | [72] |
2021 | Apoptotic vesicles | Human BMMSCs | <700nm | STS | Sequential centrifugation | Alleviate macrophages infiltration and promote macrophages polarization towards M2 phenotype | Macrophages | mice | Inject intravenously | Type 2 diabetes | [25] |
2021 | Apoptotic extracellular vesicles | Mouse BMMSCs | Around 50-250nm | STS and serum-free | Sequential centrifugation | Facilitate Fas trafficking from the cytoplasm to the cell membrane of tumor cells by evoking Ca2+ influx and elevating cytosolic Ca2+, use Fas ligand to activate the Fas-FasL pathway | Multiple myeloma cells | Mice | Inject intravenously | Multiple myeloma | [70] |
2021 | Apoptotic bodies | Mouse pOCs and mOCs | Unknown | STS | Sequential centrifugation | pOC-ABs induce EPCs differentiation and increase ECs formation, mOC-ABs induce osteogenic differentiation of MSCs and facilitate osteogenesis | EPCs, MSCs | Mice | Graft decalcified bone matrix pre-incubated with different ApoBDs in the defect area | Bone defect | [75] |
2020 | Apoptotic bodies | Murine BMMSCs | Approximately 600-1600nm | STS | Sequential centrifugation | Trigger the polarization of macrophages towards M2 phenotype | Macrophages (macrophages further enhance the migration and proliferation abilities of fibroblasts) | Mice | Locally administrate in skin wound | Skin wound | [23] |
2020 | Apoptotic bodies | Mouse T cells | 700-2000nm (ABs), 100-600nm (cABs) | STS | Sequential centrifugation | Target inflammatory regions and modulate inflammatory processes | Macrophages | Mice | Inject intravenously | Cutaneous inflammatory wound, colitis | [15] |
2020 | Apoptotic bodies | Mouse pOCs and mOCs | Approximately 1-4μm | STS | Sequential centrifugation and sequential filtering | pOC-ABs induce angiogenesis, mOC-ABs promote osteogenesis | EPCs, MC3T3-E1 | Mice | Graft decalcified bone matrix pre-incubated with different ApoBDs in the defect area | Bone defect | [29] |
2020 | Apoptotic bodies | Mouse and rat BMMSCs | 400-700nm | STS | Sequential centrifugation | Enhance angiogenesis of ECs and improve cardiac functional recovery | ECs | Rats | Inject intramyocardially | Myocardial infarction | [63] |
2019 | Apoptotic extracellular vesicles | Mouse thymocytes, Jurkat cells | 50-100nm | Gamma ray or UV irradiation | Sequential centrifugation | Promote TGFβ production in macrophages | Macrophages | Mice | Inject intraperitoneally | Colitis | [36] |
2019 | Apoptotic bodies | mOCs | Approximately 1-4μm | Nitrogen-containing bisphosphonate alendronate | Sequential centrifugation and sequential filtration | Promote osteogenic differentiation | MC3T3-E1 | N/A | N/A | N/A | [76] |
2018 | Apoptotic bodies | BMMSCs | 1-5μm | STS | Sequential centrifugation followed by sequential filtering | Maintain MSCs homeostasis and ameliorate osteopenia | BMMSCs | Mice | Inject intravenously | Osteopenia | [66] |
2009 | Apoptotic bodies | Vascular ECs | Unknown | Serum and growth factors-free | Sequential centrifugation | Convey paracrine alarm signals to recipient vascular cells that trigger the production of CXCL12 | Vascular ECs | Mice | Inject intravenously | Atherosclerosis | [77] |